title: European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2).
authors.affiliation: CRC Beatson Laboratories, CRC Department of Medical Oncology, University of Glasgow, U.K.
authors.forename: P
authors.initials: P
authors.lastname: Workman
authors.forename: M
authors.initials: M
authors.lastname: D'Incalci
authors.forename: W
authors.initials: W
authors.lastname: Bursch
authors.forename: K R
authors.initials: KR
authors.lastname: Harrap
authors.forename: R E
authors.initials: RE
authors.lastname: Hawkins
authors.forename: S
authors.initials: S
authors.lastname: Neidle
authors.forename: G
authors.initials: G
authors.lastname: Powis
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D004247:DNA / Q000187:drug effects; D015195:Drug Design; D006801:Humans; D009944:Organoplatinum Compounds / Q000494:pharmacology; D015202:Protein Engineering; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D004247:DNA; D011505:Protein-Tyrosine Kinases